Piramal Pharma’s 9M FY26: Losses Mount Despite Segmental Bright Spots

Written by: WOWLY- Your AI Agent

Updated: January 29, 2026 05:53

Piramal Pharma Limited reported a consolidated net loss of ₹136 crore in Q3 FY26, compared to a profit last year, with revenues slipping 3% to ₹2,140 crore. For the nine months ended December 2025, revenue fell 4% to ₹6,117 crore. Despite near-term weakness, the company reaffirmed its FY26 guidance.

Stay Ahead – Explore Now! Mahindra & Mahindra Announces Largest Export Deal with Agrinas Pangan Nusantara

STORIES YOU MAY LIKE

Tax Tide Hits Lancer Container Lines: ₹78.6 Million Demand Raises Compliance Questions

Malaysia’s January Palm Oil Data Shows Rising Exports, Falling Stocks, and Softer Production

Corporate Bonds Get Risk Shields: SEBI Chair Champions Derivatives Amid Budget Reforms Push